A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

Status:
COMPLETED

Trial end date:
2025-09-03

Target enrollment:

Participant gender:

This study will evaluate the safety and tolerability of SC administration of IgG in healthy participants.

PHASE1

Genentech, Inc.

Immunoglobulin G